- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | GRI Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.09. | GRI Bio Stock Rallies 37% On Positive Phase 2a Data For IPF Treatment | 6 | RTTNews | ||
| 11.09. | GRI Bio, Inc.: GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 1 | GlobeNewswire (USA) | ||
| 14.08. | GRI Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.08. | GRI Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.08. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | GRI Bio, Inc.: GRI Bio CEO, Marc Hertz, Participates in Virtual Investor "What This Means" Segment | 1 | GlobeNewswire (USA) | ||
| GRI BIO Aktie jetzt für 0€ handeln | |||||
| 31.07. | GRI Bio: Positive Biomarker-Daten in Studie zur Behandlung von Lungenfibrose | 4 | Investing.com Deutsch | ||
| 31.07. | GRI Bio reports positive interim biomarker results in IPF treatment study | 1 | Investing.com | ||
| 31.07. | GRI Bio, Inc.: GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 172 | GlobeNewswire (Europe) | Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has recommended... ► Artikel lesen | |
| 31.07. | GRI Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.07. | GRI Bio-Aktie behält Kaufempfehlung von H.C. Wainwright nach Abschluss der Phase-2a-Studie | 1 | Investing.com Deutsch | ||
| 02.07. | GRI Bio stock holds Buy rating at H.C. Wainwright as Phase 2a trial completes enrollment | 2 | Investing.com | ||
| 01.07. | GRI Bio, Inc.: GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF") | 374 | GlobeNewswire (Europe) | Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim safety... ► Artikel lesen | |
| 26.06. | GRI Bio meldet positive Sicherheitsdaten für IPF-Behandlungskandidat | 2 | Investing.com Deutsch | ||
| 26.06. | GRI Bio, Inc.: GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 250 | GlobeNewswire (Europe) | The Independent Data Monitoring Committee ("IDMC") has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate... ► Artikel lesen | |
| 26.06. | GRI Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | H.C. Wainwright REITERATES Buy rating on GRI Bio stock | 3 | Investing.com | ||
| 15.05. | GRI Bio, Inc.: GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 | 351 | GlobeNewswire (Europe) | Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") Continued momentum with completed... ► Artikel lesen | |
| 08.05. | GRI Bio, Inc.: GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 145 | GlobeNewswire (Europe) | The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,25 | +2,92 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Biontech nach Studiendaten zum Antikörper Pumitamig auf "Buy" mit einem Kursziel von 150 US-Dollar belassen. Globale Daten... ► Artikel lesen | |
| EVOTEC | 5,510 | +3,96 % | Kaufempfehlung und Großauftrag: Evotec, Nordex, Desert Gold | Sind über 100 % Kursgewinn bei der Nordex-Aktie noch nicht genug? Dies glauben jedenfalls Analysten. Zudem hat der Windturbinenhersteller auch noch einen Großauftrag an Land gezogen. Geht die Rally... ► Artikel lesen | |
| CUREVAC | 4,524 | +2,12 % | EQS-News: CureVac veröffentlicht Finanzergebnisse für das dritte Quartal und die ersten neun Monate 2025 und informiert über die Geschäftsentwicklung | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Quartals-/Zwischenmitteilung
CureVac veröffentlicht Finanzergebnisse für das dritte Quartal und die ersten neun Monate 2025 und... ► Artikel lesen | |
| AMGEN | 295,00 | +1,71 % | Hoffnung auf Zinssenkung wiederbelebt - Bitcoin, Netflix, Walmart, TJX, Amgen, Eli Lilly | Die Wall Street zeigte gestern extreme Schwankungen: Nach einem zunächst kräftigen Start kippten die Kurse im Verlauf abrupt ins Minus. Auslöser waren uneinheitliche Arbeitsmarktdaten, die die Hoffnung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,500 | +1,43 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,500 | +0,81 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Conversion | Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,430 | -4,02 % | Countdown: Höchste Biotech-Auszeichnung für NurExone?! | ||
| ABIVAX | 110,00 | +0,92 % | Truist Securities startet Coverage für Abivax mit Kaufempfehlung und hohem Kursziel | ||
| IBIO | 0,940 | -4,08 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 40,150 | +4,56 % | XFRA HDP1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILARROWHEAD PHARMAC.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,502 | -1,68 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CYBIN | 5,200 | +1,96 % | Canaccord Genuity lowers Cybin stock price target to $45 on dilution | ||
| OPGEN | 2,600 | 0,00 % | OPGEN INC - 10-Q, Quarterly Report | ||
| MEREO BIOPHARMA | 1,570 | +1,29 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 18,210 | +4,31 % | Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results | Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch... ► Artikel lesen |
Das Unternehmen GRI BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,080 Euro und damit -1,89 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GRI BIO INC finden Sie auf Wallstreet Online.